Oxidative and glycolytic skeletal muscles deploy protective mechanisms to avoid atrophy under pathophysiological iron overload
David Martin, Kévin Nay, François Robin, Amélie Rebillard, Luz Orfila, Brice Martin, Patricia Leroyer, Pascal Guggenbuhl, Suzanne Dufresne, Philippe Noirez, et al.

To cite this version:
David Martin, Kévin Nay, François Robin, Amélie Rebillard, Luz Orfila, et al.. Oxidative and glycolytic skeletal muscles deploy protective mechanisms to avoid atrophy under pathophysiological iron overload. Journal of Cachexia, Sarcopenia and Muscle, 2022, 13 (2), pp.1250-1261. 10.1002/jcsm.12897. hal-03564762

HAL Id: hal-03564762
https://hal.univ-reims.fr/hal-03564762
Submitted on 18 Jan 2023

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L’archive ouverte pluridisciplinaire HAL, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d’enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Distributed under a Creative Commons Attribution 4.0 International License
Oxidative and glycolytic skeletal muscles deploy protective mechanisms to avoid atrophy under pathophysiological iron overload

David Martin¹, Kévin Nay¹,², François Robin³, Amélie Rebillard¹, Luz Orfila¹, Brice Martin¹, Patricia Leroyer³, Pascal Guggenbuhl³, Suzanne Dufresne¹, Philippe Noirez⁴,⁵,⁶, Martine Ropert⁷, Olivier Loréal³* & Frédéric Derbré¹* (✉)

¹Laboratory ‘Movement, Sport and Health Sciences’—EA7470, University of Rennes/ENS Rennes, Bruz, France; ²Exercise and Nutrition Research Program, Mary MacKillop Institute for Health Research, Australian Catholic University, Melbourne, Vic., Australia; ³INSERM, INRAe, University of Rennes, Nutrition Metabolism and Cancer Institute (NuMeCan), Platform AEM2, CHU Rennes, Rennes, France; ⁴IRMES—Institute for Research in Medicine and Epidemiology of Sport, INSEP, Paris, France; ⁵INSERM U1244, Université de Paris, Paris, France; ⁶EA7507, Performance Health Metrology Society, Université de Reims Champagne Ardenne, Reims, France; ⁷Département de Biochimie, CHU Rennes, Rennes, France

Abstract

Background Iron excess has been proposed as an essential factor in skeletal muscle wasting. Studies have reported correlations between muscle iron accumulation and atrophy, either through ageing or by using experimental models of secondary iron overload. However, iron treatments performed in most of these studies induced an extra-pathophysiological iron overload, more representative of intoxication or poisoning. The main objective of this study was to determine the impact of iron excess closer to pathophysiological conditions on structural and metabolic adaptations (i) in differentiated myotubes and (ii) in skeletal muscle exhibiting oxidative (i.e. the soleus) or glycolytic (i.e. the gastrocnemius) metabolic phenotypes.

Methods The impact of iron excess was assessed in both in vitro and in vivo models. Murine differentiated myotubes were exposed to ferric ammonium citrate (FAC) (i.e. 10 and 50 μM) for the in vitro component. The in vivo model was achieved by a single iron dextran subcutaneous injection (1 g/kg) in mice. Four months after the injection, soleus and gastrocnemius muscles were harvested for analysis.

Results In vitro, iron exposure caused dose-dependent increases of iron storage protein ferritin (P < 0.01) and dose-dependent decreases of mRNA TfR1 levels (P < 0.001), which support cellular adaptations to iron excess. Extra-physiological iron treatment (50 μM FAC) promoted myotube atrophy (P = 0.018), whereas myotube size remained unchanged under pathophysiological treatment (10 μM FAC). FAC treatments, whatever the doses tested, did not affect the expression of proteolytic markers (i.e. NF-xB, MurF1, and ubiquitinated proteins). In vivo, basal iron content and mRNA TfR1 levels were significantly higher in the soleus compared with the gastrocnemius (+130% and +127%; P < 0.001, respectively), supporting higher iron needs in oxidative skeletal muscle. Iron supplementation induced muscle iron accumulation in the soleus and gastrocnemius muscles (+79%, P < 0.001 and +34%, P = 0.002, respectively), but ferritin protein expression only increased in the gastrocnemius (+36%, P = 0.06). Despite iron accumulation, muscle weight, fibre diameter, and myosin heavy chain distribution remained unchanged in either skeletal muscle.

Conclusions Together, these data support that under pathophysiological conditions, skeletal muscle can protect itself from the related deleterious effects of excess iron.

Keywords Sarcopenia; Disuse; Typology; Myosin heavy chain; Mitochondria

© 2022 The Authors. Journal of Cachexia, Sarcopenia and Muscle published by John Wiley & Sons Ltd on behalf of Society on Sarcopenia, Cachexia and Wasting Disorders. This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
Introduction

Extreme physical inactivity, ageing, malnutrition, and many diseases (e.g. cancer, myopathy, and acute and chronic inflammatory diseases) are recognized to promote loss of skeletal muscle mass, decreases in strength, and increased fatigue.1 Muscle wasting is a major clinical issue that contributes to reduced autonomy and quality of life, leading to increased morbidity and mortality.2 As such, understanding the cellular mechanisms involved in muscle atrophy is critical to developing efficient prevention strategies for patients, medical team, and the healthcare system.2,3 Muscle atrophy is characterized by the loss of myofibrils due to an imbalance between protein synthesis and proteolysis.4 Many molecules are identified as intracellular second messenger able to mediate cellular responses involved in muscle atrophy, including reactive oxygen species (ROS), cAMP, and calcium.4–6 Interestingly, in the last decades, iron has also been proposed as a potential second messenger or cofactor involved in skeletal muscle wasting and sarcopenia.7–9

Iron is a vital element that can accept and donate electrons readily and is involved in many essential cellular processes associated with basic functions like oxygen transport and enzymatic activity.10 Cell iron homeostasis is tightly tuned, especially through the iron response element–iron regulatory protein (IRE–IRP) system that modulates the mRNA stability or the synthesis of proteins regulating its availability and traffic, according to the cell iron levels.11 In some pathological conditions, such as hereditary haemochromatosis, repeated blood transfusions, or excess oral iron intake, systemic iron homeostasis is dysregulated and intracellular iron overload may occur. These conditions can promote the formation of ROS through the Fenton reaction leading to the oxidation of lipids, proteins, and DNA.12 Thus, iron overload impacts the function of several organs, including the liver,13 pancreas,14 bone,15 and heart.16 The development of organ iron overload in those conditions may involve the formation of abnormal biochemical forms of iron in plasma, such as the non-transferrin bound iron (NTBI), which is linked to low molecular compounds in plasma and is avidly taken up by organs, especially by liver, heart, and pancreas.17

As ~10% of total body iron is stored in skeletal muscle, the impact of iron overload on muscle phenotype has also been explored during the last decade.18 Previous studies reported a strong correlation between muscle iron accumulation occurring with ageing, ROS production, and muscle wasting.19–22 Moreover, iron overload-induced skeletal muscle atrophy has been associated with ROS-mediated ubiquitin–proteasome system activation.22–24 However, the iron supplementation used in these studies causes systemic and cellular iron overload,22–24 much higher than that observed under pathophysiological conditions, especially in patients with haemochromatosis.25

Although extra-physiological iron overload is known to induce skeletal muscle wasting, the impacts of iron excess close to pathophysiological levels on skeletal muscle mass and cellular mechanisms involved in iron homeostasis remain unclear. Therefore, the main objective of the present study was to determine the impact of pathophysiological iron overload on skeletal muscle structure and cellular adaptations. In this study, we characterized structural and metabolic adaptations occurring in skeletal muscles from iron-exposed C2C12 myotubes and iron dextran-supplemented mice. Our data support that, in conditions close to pathological situations in humans, muscle iron accumulation does not induce muscle atrophy, due to cellular adaptations, which differ according to muscle fibre type.

Material and methods

Animal experiments were approved by the Animal Experimentation Ethics Committee in accordance with the recommendations of the Guide for the Care and Use of Laboratory Animals (National Institutes of Health Publication No. 85-23, Revised 1996) and according to the European directives (86/609/European Economic Community).

Animal experiments

Two-month-old C57BL/6 male mice obtained from Janvier Labs (Le Genest-Saint-Isle, France) were randomly divided in the following two experimental groups: a group treated with one subcutaneous injection of iron dextran (1 g/kg in 200 μL) (IRON, n = 10), as previously reported26,27 and a control group that received one subcutaneous injection (200 μL) of dextran vehicle only (VEH, n = 10). All animals were maintained at the ARCHE facilities (UMS Biosit, Rennes, France) with standard conditions for temperature (19°C), atmosphere, and light (12/12 h). The animals had free access to tap water and standard food (2018 Teklad 18% Protein Rodent Diet with an iron content of 200 mg/kg). Four months after the injection, mice were deeply anaesthetized with isoflurane (2–3%). Intracardiac blood was collected in dry tubes, and the mice were euthanized by cardiac exsanguination. Blood was then centrifuged (1500 g for 10 min) for serum isolation. Soleus, gastrocnemius muscles, and liver were harvested, weighed, and frozen in liquid nitrogen or fixed in 4% paraformaldehyde.

Serum analyses

Serum iron and unsaturated iron-binding capacity (UIBC) were measured in the biochemistry laboratory (Rennes Pontchaillou Hospital) on Roche Cobas® 8000 analyser (Cobas
Iron quantifications in liver and skeletal muscles

Hepatic and skeletal muscle iron pool has been quantified on the ‘Analyse Élémentaire et Métabolisme des Métaux’ (AEM2) Platform (Université de Rennes 1—Centre Hospitalier Universitaire). Frozen skeletal muscle and liver samples were desiccated at 120°C for 15 h in an overnight. They were weighed and mineralized according to a previous protocol. Brieﬂy, nitric acid solution (Optima Grade, Thermo Fisher Scientiﬁc, Waltham, MA, USA) was added to dried samples, and then the tubes were placed in a MARSI microwave (CEM, Matthews, NC, USA) with a temperature maintained at 180°C. Iron (56Fe) was quantiﬁed by inductively coupled plasma mass spectrometry on an X-Series IO from Thermo Fisher Scientiﬁc equipped with collision cell technology (AEM2 platform). Calibration ranges were prepared using a multi-element calibrator solution (Plasma Cal, SCP SCIENCE, Baie-D’Urfe, QC, Canada).

Histological analysis

Gastrocnemius muscles were ﬁxed in paraformaldehyde 4% during 24 h and then embedded in parafﬁn. Serial transverse sections of 4 μm were cut from the wider part of each sample using a Leica microtome and were mounted on glass slides (three sections per slide). Muscle sections were then stained using Gomori’s method to detect reticulin ﬁbres. All stained sections were scanned (×20 objective) to measure the ﬁbre cross-sectional area from at least 300 ﬁbres per muscle using the Image-Pro Plus software 6.0 (Media Cybernetics, Inc.).

Muscle ﬁbre phenotype

The muscle ﬁbre phenotype was determined by assessing the presence of the different myosin heavy chain (MHC) isoforms (slow MHC I and fast MHC Iα, Iαd/x, and Iαb isoforms), as previously described. Protein samples (6 μg) were separated on high-glycerol-containing (30%) gels with an acrylamide-to-bis-acrylamide ratio of 50:1 for the separating gel (8% total acrylamide, pH 8.8) and for the stacking gel (4% total acrylamide, pH 6.8) using a MINI-PROTEAN IO dual slab cell apparatus (Bio-Rad Laboratories, Inc., Hercules, CA, USA). After electrophoresis (at 140 V in a refrigerated room at 4°C for 22 h), gels were stained with Coomassie blue (IRDye® Blue Protein Stain, LI-COR Biosciences, Lincoln, NE, USA), and the different MHC isoforms were identiﬁed according to their electrophoretic mobility pattern.

Cell culture

C2C12 murine myoblasts obtained from ECACC (91033101) were grown in Dulbecco’s modiﬁed Eagle’s medium (25 mM glucose, Gibco, USA) supplemented with 10% foetal bovine serum (Gibco) and 1% penicillin/streptomycin/glutamine (Gibco) in a humididiﬁed atmosphere with 5% CO2 at 37°C. When cells reached 70–5% conﬂuence, the medium was changed to Dulbecco’s modiﬁed Eagle’s medium supplemented with 2% horse serum (Gibco) to induce differentiation. The induction medium was changed every day during the next 5 days. Then, differentiated myotubes were treated in serum-free medium with 10 and 50 μM of ferric ammonium citrate (FAC) for different times depending on the experiments.

Measurement of myotube size

After 72 h of FAC treatment, myotubes were ﬁxed in 4% paraformaldehyde for 10 min, washed in phosphate-buffered saline (PBS) 1×, and then permeabilized with PBS–bovine serum albumin (BSA) 2%–saponin 0.2% for 30 min. Cells were then incubated at room temperature with an anti-pan MHC antibody (MyH, sc-20641, Biotechnology) for 2 h and washed in PBS 1× before staining with a secondary goat anti-rabbit immunoglobulin (Alexa Fluor 488, 1:2000 dilution, Cell Signaling) for 1 h. The images were visualized with a ﬂuorescence microscope (Axio Observer Z1, Zeiss, Germany). Myotube size was quantiﬁed by measuring diameter of 200 myotubes for each condition from 10 random ﬁelds at ×20 magniﬁcation using ImageJ software. Three diameter measurements were taken along the length of each myotube, and the mean diameter was calculated.

RNA extraction and reverse transcription–real-time PCR

After 24 h of FAC exposure, myotubes were washed in cold PBS and centrifuged, and the cell pellet was then frozen in liquid nitrogen. Skeletal muscles from in vivo experiments were ground in liquid nitrogen, and the obtained powder was used to perform experiments. Total RNA was extracted using TRIzol® reagent according to the manufacturer’s protocol (Sigma–Aldrich). RNA extraction was directly realized on frozen C2C12. RNA amounts were determined by NanoDrop spectrophotometer, and RNA quality was controlled on 1.2% agarose gel using the FlashGel electrophoresis system (Lonza). Reverse transcription reaction (RT) was carried out on 1 μg of total RNA (Scriptscript reverse transcription, 170-8840). Then, real-time PCR experiments were performed on RT products in a ﬁnal volume of 10 μL containing 5 μL of cDNA (diluted at 1/5), 0.2 μL of primers (10 μM), and 12 μL of Reagents 03183696 122 and 04536355190, respectively, Roche Diagnostics, Meylan, France). Serum transeferrin saturation was calculated as [serum iron/(serum iron + UIBC)] × 100 and expressed as percentage.
4.8 μL of SYBR® Green Supermix (1725271, Bio-Rad Laboratories, Inc.). Experiments were monitored in CFX Real-Time machine (Bio-Rad Laboratories, Inc.). The expression of target genes was normalized to reference genes, and the relative expression was calculated using the ΔΔCt method. Primer sequences are listed in Table 1. The reference genes were ribosomal protein L4 (Rpl4) and ribosomal protein L19 (Rpl19).

### Cytosolic protein extraction

After 72 h of FAC exposure, myotubes were washed in cold PBS and centrifuged, and the cell pellet was then frozen in liquid nitrogen. Skeletal muscles from in vivo experiments were ground in liquid nitrogen, and the obtained powder was used to perform experiments. Cytosolic protein extraction was performed from soleus, gastrocnemius, and C2C12 in cold lysis buffer containing 10.0 mM Tris-HCl, pH 7.4, 0.5 M sucrose, 50.0 mM NaCl, 5.0 mM EDTA, 30.0 mM NaF, 100.0 M sodium orthovanadate, and protease inhibitor cocktail (5 L/mL, P8340; Sigma, St. Louis, MO, USA). The samples were homogenized using a Polytron homogenizer at 4°C. Each sample was then incubated on ice for 30 min followed by 10 s of sonication. The homogenates were then transferred to microcentrifuge tubes and centrifuged at 12 000 g for 12 min at 4°C. The protein concentration of the supernatant was determined by a Lowry assay using bovine serum albumin as a standard.

### Western blotting

Samples were diluted in SDS-PAGE sample buffer (50 mM Tris-HCl, pH 6.8, 2% SDS, 10% glycerol, 5% mercaptoethanol, and 0.1% bromophenol blue) and heated 5 min at 95°C until analyses. Samples containing 50 μg of proteins were resolved on 10% or 12.5% SDS-PAGE. The proteins were transferred at 240 mA for 90 min onto a 0.2 μm nitrocellulose membrane. Membranes were blocked with 5% BSA or non-fat dry milk in Tris-buffered saline/0.05% Tween 20 (TBST) for 1 h at room temperature. Membranes were incubated overnight at 4°C with appropriate primary antibodies (Table 2). Thereafter, membranes were washed with TBST and incubated for 1 h at room temperature with infrared dye-conjugated secondary antibodies (LI-COR Biosciences). After being washed, blots were captured using the Odyssey Imaging System (LI-COR Biosciences). All blots were scanned, and densitometry analysis of the bands was conducted using GS-800 imaging densitometer and Quantity One software (Bio-Rad Laboratories, Inc.). All blots were corrected for loading based on the HSC70 expression.

### Protein carbonylation

Quantification of protein carbonyl levels was performed using an OxyBlot® kit according to the manufacturer’s protocol (S7150, Millipore, Île-de-France, France). Cytosolic protein extracts from soleus and gastrocnemius (15 μg) were derivatized with 1% DNPH for 15 min at RT and then separated on 10% SDS-PAGE. After transfer, membranes were blocked successively incubated in 1% BSA in PBS/0.05% Tween 20 (TBST) for 1 h at room temperature. Membranes were incubated overnight at 4°C with appropriate primary antibodies (Table 2). Thereafter, membranes were washed with TBST and incubated for 1 h at room temperature with infrared dye-conjugated secondary antibodies (LI-COR Biosciences). After being washed, blots were captured using the Odyssey Imaging System (LI-COR Biosciences). All blots were scanned, and densitometry analysis of the bands was conducted using GS-800 imaging densitometer and Quantity One software (Bio-Rad Laboratories, Inc.). All blots were corrected for loading based on the HSC70 expression.

### Table 2

| Protein | Reference | Source | Dilution |
|---------|-----------|--------|----------|
| 4-HNE   | Abcam, ab46545 | Rabbit | 1/1000 |
| COXIV   | Cell Signaling, 4850 | Rabbit | 1/1000 |
| Cytochrome c | Santa Cruz, sc13156 | Mouse | 1/2000 |
| DMT1    | Santa Cruz, sc166884 | Mouse | 1/200 |
| FTH     | Abcam, ab65080 | Rabbit | 1/1000 |
| HSC70   | Santa Cruz, sc7298 | Mouse | 1/5000 |
| MHC     | Santa Cruz, sc25619 | Rabbit | 1/200 |
| MUrF1   | Abcam, ab183094 | Rabbit | 1/1000 |
| p-4EBP1 | Cell Signaling, 2855 | Rabbit | 1/1000 |
| p-AK4e73 | Cell Signaling, 9271 | Rabbit | 1/1000 |
| Akt     | Cell Signaling, 9272 | Rabbit | 1/1000 |
| NFx8p65 | Cell Signaling, 4764 | Rabbit | 1/1000 |
| TFR1    | Cell Signaling, 13113 | Rabbit | 1/1000 |
| Ubiquitin (Ub) | Cell Signaling, 3933 | Rabbit | 1/1000 |

*DOI: 10.1002/jcsm.12897*
Tween 20 (PBST) during 1 h and then overnight at 4°C with anti-DNP primary antibody (1:200) supplied in the OxyBlot kit. Thereafter, membranes were washed with PBST and incubated for 1 h at room temperature with infrared dye-conjugated secondary antibodies (LI-COR Biosciences). After being washed, blots were captured using the Odyssey Imaging System (LI-COR Biosciences).

4-Hydroxy-2-nonenal analysis

Detection of 4-hydroxy-2-nonenal (4-HNE) protein adducts was performed as previously described. Briefly, membranes were incubated in a solution of 250 mM sodium borohydride in 100 mM MOPS, for 30 min at RT, immediately after transfer. Membranes were blocked with 1% BSA PBST during 1 h and then incubated overnight at 4°C with the primary antibody (Table 2). Thereafter, membranes were washed with PBST and incubated for 1 h at room temperature with infrared dye-conjugated secondary antibodies (LI-COR Biosciences). After being washed, blots were captured using the Odyssey Imaging System (LI-COR Biosciences).

Statistical analyses

All data are presented as the mean ± standard deviation. The normality of each distribution and homogeneity of variance were assessed with the Shapiro–Wilk and Levene tests, respectively. Student’s t-test was chosen when the normality and/or equal variance was checked using Kruskal–Wallis and Dunn’s post hoc tests have been performed. For all statistical analyses, the significance level was set at 0.05. Data were analysed using the statistical package GraphPad Prism Version 7.00 for Windows (GraphPad Software, La Jolla, CA, USA).

Results

Responses of differentiated myotubes to ferric ammonium citrate treatment

Figure 1 presents the expression of iron metabolism genes and proteins in differentiated myotubes when exposed to 10 or 50 μM FAC, a form of NTBI. A 72 h treatment with FAC induces an increase in ferritin protein expression in myotubes. This effect seems to be dose dependent (7-fold and 13-fold increase for 10 and 50 μM, *P < 0.002 and *P < 0.001, respectively, Figure 1B and 1C). A concomitant gradual decrease in mRNA TfR1 levels is also detected (−76% and −91% for 10 and 50 μM, *P < 0.001, respectively, Figure 1A). Only 50 μM FAC induced a significant reduction in TfR1 protein levels (−50%, *P = 0.031, Figure 1B and 1C). Interestingly, Fpn mRNA level significantly increases for 10 and 50 μM FAC (2.8-fold change for both, *P < 0.001, Figure 1A). Finally, mRNA coding for other iron transport proteins (i.e. DMT1 and Zip14), iron storage (i.e. FTH), iron–sulfur proteins (i.e. Aco1 and Cyt c), myoglobin, and autophagy-related proteins (i.e. Atg5 and Atg7) remains unaffected by exposure to FAC.

Figure 1 Responses of C2C12 differentiated myotubes to FAC treatment. Differentiated C2C12 myotubes were exposed to various concentrations of FAC (10 and 50 μM) in serum-free medium for 24 h (qPCR analyses) or 72 h (western blot analyses). (A) Iron metabolism gene expression in response to FAC 10 and 50 μM. (B) Iron metabolism protein expression in response to FAC 10 and 50 μM. (C) Representative blotting images used for the quantification shown in (B). Values are the mean ± SD. The experiments were performed on three independent replicates of three dependent samples for each condition. Significance was checked using Kruskal–Wallis and Dunn’s multiple comparisons. Significance between conditions (*P < 0.05, **P < 0.01, and ***P < 0.001, respectively). Aco1, aconitate 1; Atg5, autophagy-related 5; Atg7, autophagy-related 7; Cyc1, cytochrome c; Dmt1, divalent metal transporter 1; Fpn, ferroportin; FTH, ferritin heavy chain; HSC70, heat shock cognate 71 kDa protein; Tfr1, transferrin receptor 1; Zip14, ZRT/IRT-like protein 14.
Impact of ferric ammonium citrate treatment on myotube size and signalling pathway involved in muscle mass regulation and mitochondrial function

In differentiated myotubes, we observed that 10 μM FAC does not affect myotube size, but that 50 μM FAC significantly decreases this parameter compared with non-treated myotubes (−11%, \( P = 0.018 \), Figure 2A and 2B). MHC protein content remains unchanged under 10 and 50 μM (Figure 2C and 2D). FAC exposures are not associated to significant changes in protein expression involved in proteolysis signalling pathways (i.e. NF-κB, Akt, p-Akt, eukaryotic translation initiation factor 4E-binding protein 1; 4EBP1, COXIV, cytochrome c oxidase IV; Cyt c, cytochrome c; HSC70, heat shock cognate 71 kDa protein; Murf1, muscle RING-finger protein-1; MHC, myosin heavy chain; Nf-κB, nuclear factor-xB; Ub Prot, polyubiquitinated proteins).

Impact of ferric ammonium citrate treatment on myotube size and signalling pathway involved in muscle mass regulation and mitochondrial function

In differentiated myotubes, we observed that 10 μM FAC does not affect myotube size, but that 50 μM FAC significantly decreases this parameter compared with non-treated myotubes (−11%, \( P = 0.018 \), Figure 2A and 2B). MHC protein content remains unchanged under 10 and 50 μM (Figure 2C and 2D). FAC exposures are not associated to significant changes in protein expression involved in proteolysis signalling pathways (i.e. NF-κB, Akt, p-Akt, eukaryotic translation initiation factor 4E-binding protein 1; 4EBP1, COXIV, cytochrome c oxidase IV; Cyt c, cytochrome c; HSC70, heat shock cognate 71 kDa protein; Murf1, muscle RING-finger protein-1; MHC, myosin heavy chain; Nf-κB, nuclear factor-xB; Ub Prot, polyubiquitinated proteins).

Iron overload does not cause muscle atrophy

Iron overload does not cause muscle atrophy.
MurF1, and ubiquitinated proteins) or in mitochondrial function (i.e. cyt c and COXIV). Finally, we found that the Akt activation (i.e. pAkt/Akt) is significantly reduced in myotubes exposed to 50 μM FAC (−53%, $P = 0.0035$, Figure 2C and 2D).

**Iron metabolism differs between oxidative and glycolytic skeletal muscles**

We first observed that iron content is significantly higher in the soleus compared with the gastrocnemius in both treated...
and non-treated mice (+130% and +78%, \( P < 0.001 \), respectively, *Figure 3D*). We also found that mRNA and protein levels of TfR1 are significantly higher in the soleus compared with the gastrocnemius (+127% and +239%, respectively, \( P < 0.05 \), *Figure 4A–4C*). Dmt1 mRNA levels do not differ between the two muscles, whereas DMT1 protein levels are significantly higher in the soleus compared with the gastrocnemius (+161%, \( P < 0.05 \), *Figure 4B and 4C*). On contrary, FtH mRNA levels are significantly lower in the soleus compared with the gastrocnemius (−38%, \( P < 0.001 \), *Figure 4A*), whereas FtH protein levels do not differ between these skeletal muscles (Figure 4B and 4C). Whereas Aco1 mRNA levels do not differ between soleus and gastrocnemius, the protein levels of cytochrome c are significantly higher in the soleus compared with the gastrocnemius (+59%, \( P < 0.001 \), *Figure 4B and 4C*).

**Iron supplementation causes iron overload in oxidative and glycolytic skeletal muscle**

Four months after iron dextran injection, transferrin saturation and serum iron concentration significantly increase compared with the vehicle group (+68%, \( P < 0.001 \) and +92%, \( P < 0.001 \), respectively, *Figure 3A and 3B*). The results are associated with a very high increase of iron content in the liver of iron-treated mice compared with non-treated mice (+3944%; \( P < 0.001 \), *Figure 3C*). Iron supplementation also induces significant increases of iron content in both the soleus (i.e. oxidative) and gastrocnemius (i.e. glycolytic) muscles (+34%; \( P = 0.002 \) and +79%, \( P < 0.001 \), respectively, *Figure 3D*).

**Muscle adaptations of iron metabolism under iron supplementation**

We observed that iron dextran injection tends to increase the iron storage ferritin protein expression in the gastrocnemius after 4 months (+36%; \( P = 0.06 \), *Figure 4E and 4F*), whereas it remains unchanged in the soleus (*Figure 4H and 4I*). mRNA and protein levels of other iron metabolism proteins (i.e. TfR1, DMT1, and FPN) remain unaffected both in the soleus and in the gastrocnemius in iron-treated animals (*Figure 4D–4I*). 4-HNE protein adducts and carbonylated proteins levels, quantified in order to assess oxidative damage in so-

---

**Figure 5** Iron supplementation does not induce oxidative damage in skeletal muscle. (A) 4-HNE protein adducts and carbonylated proteins in gastrocnemius. (B) Representative blotting images for 4-HNE protein adducts in gastrocnemius. (C) Representative blotting images for carbonylated proteins in gastrocnemius. (D) 4-HNE protein adducts and carbonylated proteins in soleus. (E) Representative blotting images for 4-HNE protein adducts in soleus. (F) Representative blotting images for carbonylated proteins in soleus. Values are the mean ± SD (\( n = 7–9 \) per group). Significance was checked using Mann–Whitney \( U \) test or Student’s unpaired \( t \)-test.
leus and gastrocnemius, are not significantly affected in gastrocnemius (Figure 5A–5C) and soleus (Figure 5D–5F).

Iron supplementation does not impact skeletal muscle structure in mice

Four months after iron dextran injection, the soleus and gastrocnemius weight-to-body ratio remain unchanged in iron-treated mice compared with non-treated mice (Figure 6A). Similarly, iron supplementation does not affect gastrocnemius muscle fibre diameter (Figure 6B–6D). MHC distribution in the soleus (Figure 6E and 6G) and gastrocnemius muscles (Figure 6F and 6G) does not significantly change in iron-treated mice.

Discussion

The aim of the present study was to investigate whether iron overload reflecting pathophysiological conditions impacts skeletal muscle structure, cellular mechanisms regulating iron metabolism, or muscle atrophy. In response to iron overload close to clinically relevant levels, our data contrast with previous studies, as excess iron did not induce muscle atrophy. Indeed, FAC-treated myotubes and iron dextran supplementation in mice induced iron accumulation in cells and skeletal muscle, but neither muscle atrophy nor activation of key signalling pathways involved in proteolysis. These data suggest that skeletal muscles can protect themselves from excess iron and its related deleterious effects through cellular mechanisms, which depend on muscle fibre type.

In basal condition, the 2.5-fold higher level of iron content we reported in the mice soleus compared with the gastrocnemius is in accordance with the metabolic phenotype of these two skeletal muscles. The soleus is an oxidative skeletal muscle dense in mitochondria with slow contractile properties that requires more energy, and therefore iron, compared with a fast-glycolytic muscle such as the gastrocnemius. This higher demand for iron of this muscle is reflected by the higher TfR1 protein levels in the soleus muscle, suggesting a potential link between oxidative metabolism and iron import. Altogether, the data suggest that mitochondria could drive the uptake of transferrin iron to meet the higher cellular needs of this oxidative muscle. Despite the higher level of ferritin mRNA levels in the gastrocnemius compared with the soleus, the ferritin protein itself is expressed at a similar level in both muscles. These findings reflect the fact that the cellular machinery may perfectly balance the iron uptake according to cellular iron needs. The IRP–IRE system is one of the main intracellular iron metabolism regulators due to its role in the control of transferrin receptor 1 mRNA stability and ferritin protein translation in a
Iron overload does not cause muscle atrophy

coordinated manner through interactions with IRE sequences located in 3′ and 5′ untranslated mRNA region, respectively.11 The increase of TfR1 protein levels reported in the soleus could then likely involve the IRE–IRP system. Notably in the gastrocnemius, there was no increase in ferritin protein levels despite the ferritin mRNA levels being higher. Again, such findings could indicate that the IRE–IRP system neutralizes the impact of the higher ferritin mRNA level, the synthesis of this iron storage protein being in equilibrium with the lower cellular iron content in this glycolytic muscle. In myotubes exposed to iron, we observed a decrease of TfR1 mRNA levels combined with an increase of ferritin protein levels that, together with dose dependency, strongly support a role of the IRE–IRP system in the control of iron metabolism in muscle cells.

Despite excess iron, we did not observe muscle atrophy in either in vitro or in vivo conditions. Indeed, differentiated myotubes are protected from atrophy under 10 μM FAC, corresponding to levels of free iron close to serum NTBI levels observed in hereditary haemochromatosis or β-thalassemia patients (i.e. between 1 and 10 μM).37,38 We also exposed myotubes higher doses of FAC (i.e. 50 μM), which is in a range far above the NTBI values observed in iron overloaded patients, even in thalassemia.38,39 In response to this very high dose, we found a significant slight reduction of myotube size. Despite the fact that the content of proteins involved in proteolysis pathways (i.e. NF-κB, MurF1, and ubiquitinated proteins) remained unchanged, a significant decrease of Akt activation level was found when exposing myotubes to 50 μM FAC. A similar observation was previously reported by others in differentiated myotubes exposed to higher doses of iron (i.e. 100 μM iron sulfate).23 Akt is a protein kinase playing a central role in muscle metabolism by regulating insulin-dependent glucose uptake and protein synthesis.40,41 In contrast to a previous study,23 our data suggest that the atrophic effect of iron excess is only found (i) with very high, and not clinically relevant levels of NTBI, and (ii) seems more related to an inhibition of anabolic processes more than an activation of catabolic pathway. Such a hypothesis should be explored in further experiments. Together, our data suggest that pathophysiologically iron overload does not induce skeletal muscle atrophy in vitro probably due the IRE–IRP system protecting against iron excess.

The parenteral iron supplementation that we performed in mice has been previously shown to lead to an iron overload in both parenchymal cells and macrophages.26,27 In accordance to these data, we report blood iron parameters in iron-treated mice close to those observed in hereditary haemochromatosis patients (i.e. transferrin saturation >55%, serum iron levels >27 μmol/L, and liver iron content >8000–10 000 μg/g).42,43 These results are also in accordance with the range of serum iron levels and transferrin saturation we also observed in 6-month-old Hfe−/− mice (Supporting Information, Figure S1). In parallel, the muscle iron concentrations increase both in the soleus and in the gastrocnemius of iron supplemented animals, whatever the contractile and metabolic phenotype. Notably, these elevations of iron concentrations are associated to an increase of ferritin protein levels in gastrocnemius, but not in soleus. Interestingly, we report similar increase of ferritin protein levels in gastrocnemius of Hfe−/− mice, whereas these levels remain also unaffected in soleus of those animals (Figure S1). Altogether, such data support that mechanisms of adaptation to chronic iron overload may differ depending on muscle fibre type.

The ability of labile cytosolic ‘free’ iron to generate oxidative damage is currently considered as the main mechanism proposed to explain whether iron excess promotes muscle atrophy.21,23,24 However, despite elevations of muscle iron concentrations in iron supplemented animals, we observed that neither 4-HNE protein adducts nor carbonylated proteins levels increase in soleus and gastrocnemius. These data suggest that skeletal muscles, whatever its typology and metabolism, can adapt to an iron excess close to situations observed in humans and protect themselves from potential oxidative damage. In accordance with these findings and our in vitro results, no reduction in muscle weight and fibre size compared with control animals was observed in iron-treated mice. Such data contrast with previous studies reporting that iron overload promotes skeletal muscle atrophy in mice.23,24,32 However, experimental protocols used in those studies induced a systemic and muscle iron overload largely beyond the classical findings observed in pathophysiological conditions. Here, we used an experimental murine model iron overload,26,27 which involved injecting a unique dose of iron dextran to animals (1 g/kg), corresponding to an absolute dose of iron range from 25 to 35 mg. Four months after the injection, we reported a clinical picture of a high iron overload with blood parameters similar to those observed in humans.42,43 On contrary, Reardon et al. injected iron dextran several times over a month to a total of dose of 200 mg,24 whereas Ikekda et al. injected a total of 140 mg in only 2 weeks of treatment.23 As the body’s iron metabolism functions in a very closed system with very low daily losses, these treatments promote extra-physiological iron overloads that are relevant for studying intoxication or poisoning, but not for extrapolations in chronic iron overload condition. Thus, Reardon et al. observed plasma iron levels around 290 μmol/L in iron-treated mice,24 which was 10-fold higher than the levels reported in our mice and is never found in humans. In addition, our findings are consistent with the recent study of Liang et al. reporting a four-fold increase of iron content in the soleus without reduction of muscle weight after a 2 week treatment with a total of 40 mg of iron dextran injected in animals, which is closer to our doses.44 Interestingly, a significant reduction of soleus maximal muscle strength was reported in this study independently from a re-
duction of muscle mass. A disturbance in the muscle redox balance and sarcoplasmic reticulum Ca\(^{2+}\) release was proposed as potential mechanisms to explain this reduction of muscle strength. In our study, we also questioned the impact of iron excess on muscle contractile phenotype recognized to affect maximal muscle strength independently from muscle mass. We found that MHC distribution remains unchanged after 4 months in both the soleus and gastrocnemius muscles, suggesting that contractile phenotype would not be impacted by iron excess.

In summary, our data highlight that despite the distinct iron metabolism phenotype of oxidative and glycolytic skeletal muscles in a basal state, pathophysiological iron overload does not cause skeletal muscle atrophy in mice. Therefore, in a clinically relevant condition, skeletal muscles seem able to protect themselves from the excess iron and its related deleterious effects. This study opens new perspectives to improve the management of patients exhibiting skeletal muscle wasting conditions in which muscle iron accumulation may occur, including ageing, myopathy, and disuse.

Acknowledgements

The authors thank Pascale Bellaud (H2P2 facility, University Rennes 1, Rennes) for technical help with histological analyses. The authors also thank Clara Filippini for manuscript editing.

Online supplementary material

Additional supporting information may be found online in the Supporting Information section at the end of the article.

Conflict of interest

No conflict of interest, financial or otherwise, is declared by the authors.

References

1. Powers SK, Lynch GS, Murphy KT, Reid MB, Zijdewind I. Disease-induced skeletal muscle atrophy and fatigue. Med Sci Sports Exerc 2016;48:2307–2319.
2. Covinsky KE, Palmer RM, Fortinsky RH, Cournell SR, Stewart AL, Kresevic D, et al. Loss of independence in activities of daily living in older adults hospitalized with medical illnesses: increased vulnerability with age. J Am Geriatr Soc 2003;51:451–458.
3. Hermans G, Van den Berge G. Clinical review: intensive care unit acquired weakness. Crit Care 2015;19:274.
4. Pierre N, Appriou Z, Gratas-Delamarche A, Derbré F. From physical inactivity to immobilization: dissecting the role of oxidative stress in skeletal muscle insulin resistance and atrophy. Free Radic Biol Med 2016;98:197–207.
5. Bonaldo P, Sandri M. Cellular and molecular mechanisms of muscle atrophy. Dis Model Mech 2013;6:25–39.
6. Silveira WA, Gonçalves DA, Machado J, Lautherbach N, Lustrino D, Paula-Gomes S, et al. CAMK-dependent protein kinase inhibits FoxO activity and regulates skeletal muscle plasticity in mice. FASEB J 2020;34:12946–12962.
7. Halon-Golabek M, Borkowska A, Herman-Antosiewicz A, Antosiewicz J. Iron metabolism of the skeletal muscle (SFR) and the French Centre National d’Etudes Spatiales (CNES).

Funding

This study was supported by grants from the French Society for Rheumatology [Société Française de Rhumatologie (SFR)] and the French Centre National d’Etudes Spatiales (CNES).
Iron overload does not cause muscle atrophy

20. Hofer T, Marzetti E, Xu J, Seo AY, Gulec S, Knutson MD, et al. Increased iron content and RNA oxidative damage in skeletal muscle during aging and disuse atrophy. *Exp Gerontol* 2008;43:563–570.

21. Jung SH, DeRuisseau LR, Kavazis AN, Kobak K, Kasztura M, Dziegala M, Bania J, Reardon TF, Allen DG. Iron injections prevent this process in the hypoxic conditions. *Int J Mol Med* 2018;41:2678–2686.

22. Ikeda Y, Imao M, Satoh A, Watanabe H, Hamano H, Horinouchi Y, et al. Iron injection promotes the atrophy of skeletal myocytes, whereas iron supplementation prevents this process in the hypoxic conditions. *Int J Mol Med* 2018;41:2678–2686.

23. Reardon TF, Allen DG. Iron injections in mice increase skeletal muscle iron content, induce oxidative stress and reduce exercise performance. *Exp Physiol* 2009;94:720–730.

24. Brissot P, Loréal O. Iron metabolism and related genetic diseases: a cleared land, molybdenum, and manganese concentrations are coregulated in hepcidin-deficient and secondary iron overload models in mice. *FASEB J* 2019;33:9551–9564.

25. Picard M, Hepple RT, Burelle Y. Mitochondrional functional specialization in glycolytic and oxidative muscle fibers: tailoring the organelle for optimal function. *Am J Physiol Cell Physiol* 2011;302:C629–C641.

26. Pigeon C, Ilyin G, Courseaud B, Leroyer P, Turlin B, Brissot P, et al. A new mouse liver-specific gene, encoding a protein homologous to human antimicrobial peptide hepcidin, is overexpressed during iron overload. *J Biol Chem* 2001;276:7811–7819.

27. Mühlenhoff U, Hoffmann B, Richter N, Rietzschel N, Spantgar F, Stehling O, et al. Compartmentalization of iron between mitochondria and the cytosol and its regulation. *Eur J Cell Biol* 2015;94:292–308.

28. Al-Refaie FN, Wickens DG, Wonke B, Kostoglou-Hedges GJ, Hoffbrand AV. Serum non-transferrin-bound iron in beta-thalassemia major patients treated with desferrioxamine and L1. *Br J Haematol* 1992;82:431–436.

29. Sherwood RA, Pippard MJ, Peters TJ. Iron homeostasis and the assessment of iron status. *Ann Clin Biochem* 1998;35:693–708.

30. Al-Refaie FN, Wickens DG, Wonke B, Kostoglou-Hedges GJ, Hoffbrand AV. Serum non-transferrin-bound iron in beta-thalassemia major patients treated with desferrioxamine and L1. *Br J Haematol* 1992;82:431–436.

31. Vinchi F. Non-transferrin-bound iron in the spotlight: novel mechanistic insights into the vasculotoxic and atherosclerotic effect of iron. *Antioxid Redox Signal* 2021;35:387–414.

32. Sherwood RA, Pippard MJ, Peters TJ. Iron homeostasis and the assessment of iron status. *Ann Clin Biochem* 1998;35:693–708.